n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide has been researched along with erlotinib hydrochloride in 1 studies
| Studies (n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide) | Trials (n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide) | Recent Studies (post-2010) (n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide) | Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) |
|---|---|---|---|---|---|
| 18 | 5 | 13 | 4,353 | 786 | 3,033 |
| Protein | Taxonomy | n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide (IC50) | erlotinib hydrochloride (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1683 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 1.705 | |
| Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.04 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asada, M; Funahashi, Y; Ito, K; Semba, T; Uenaka, T; Wakabayashi, T | 1 |
1 other study(ies) available for n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and erlotinib hydrochloride
| Article | Year |
|---|---|
Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Indoles; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |